More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances

Eitemau Tebyg

• Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
  gan: Rose, R H, et al.
  Cyhoeddwyd: (2014)
• Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter
  gan: Emoto, C, et al.
  Cyhoeddwyd: (2016)
• PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants
  gan: Emoto, Chie, et al.
  Cyhoeddwyd: (2018)
• PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3
  gan: Yoshikado, Takashi, et al.
  Cyhoeddwyd: (2018)
• Pre-incubation with everolimus and sirolimus reduces organic anion transporting polypeptide (OATP)1B1- and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing OATP1B1- and OATP1B3-mediated drug-drug interactions
  gan: Farasyn, Taleah, et al.
  Cyhoeddwyd: (2019)